Marco Pravetoni, PhD

Faculty Appointment(s)

Professor

Rick L. Seaver Endowed Professorship for Brain Wellness

mprave@uw.edu

The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are: 1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose, 2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients, 3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms, 4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2), 5) biosensors for field detection or diagnosis.

Education

PhD in Pharmacology, University of Minnesota, 2008

Department Affiliations

Centers/Programs

Scholarly Expertise

  • Vaccines, monoclonal antibodies, immunology, pharmacology, chemical threats, immunoprofiling

Recent Publications

A humanized monoclonal antibody attenuates carfentanil self-administration in nonhuman primates.
(2025 Sep)
Drug Alcohol Depend Rep 16(): 100365
Galbo-Thomma LK, Baehr C, Gay EA, Runyon S, Pravetoni M, France CP
Safety and Toxicological Evaluation of Subunit Keyhole Limpet Hemocyanin-Loaded Lipid-PLGA Hybrid Nanoparticles (sKLH-hNPs) as a Nanocarrier for an Opioid Use Disorder Vaccine.
(2025 Jul 5)
Int J Toxicol
Walter D, Ci Q, Hu H, DeHority R, Hinckley J, Bian Y, Serpa PBS, Southard T, Werre SR, Pravetoni M, Ehrich M, Zhang C
A novel cationic liposome-formulated toll like receptor (TLR) 7/8 agonist enhances the efficacy of a vaccine against fentanyl toxicity.
(2025 Aug 10)
J Control Release 384(): 113901
Hamid FA, Le NN, Song D, Amin H, Hicks L, Bird S, Siram K, Hoppe B, Demeler B, Evans JT, Burkhart DJ, Pravetoni M
In vitro biophysical and pharmacological profiling predicts in vivo efficacy of anti-carfentanil monoclonal antibodies in mice.
(2025 Jul 12)
Biochem Biophys Res Commun 770(): 151995
Hoppe BK, Seaman RW Jr, Hannon B, Gay E, Hicks D, Baehr C, Hill HJ, Pandit SG, Baldridge A, Berner V, AuCoin DP, Runyon S, Pravetoni M
Bivalent Hapten Display Strategies for Conjugate Vaccines Targeting Opioid Mixtures Containing Fentanyl.
(2025 Apr 16)
Bioconjug Chem 36(4): 676-687
Baehr C, Jahan R, Gebo A, Vigliaturo J, Song D, Rahman MT, Tronconi D, Khaimraj A, Seaman R, Marecki C, Kim CM, Persano S, Runyon SP, Pravetoni M
Show complete publication list »
Edit Profile